Roche’s Tecentriq has won US clearance for use in combination with carboplatin and etoposide (chemotherapy) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) in the US, offering patients the first new treatment in more than 20 years.
Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in the front-line maintenance setting for ovarian cancer.
Sage Therapeutics’ Zulresso has become first treatment to be approved for post-partum depression in the US.
GlaxoSmithKline group Tesaro has presented mid-stage data indicating “robust activity” of its anti-PD-1 therapy dostarlimab in patients with advanced or recurrent endometrial cancer, with a filing now on the cards for later this year.
Unique in the industry, the PharmaTimes Communications Team of the Year competition gives communications professionals the opportunity to demonstrate their skills in a live environment, developing a strategic and tactical programme in response to a fictional, but realistic challenge.
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
Scientists have developed and tested a vaccine that they say could be used to treat chronic pain caused by osteoarthritis.
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.
Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.
New iron-trial results have paved the way for improved haemodialysis treatment.
The Lewy Body Society has announced that the latest recipients of its grant programme will be University of Cambridge, Newcastle University and Imperial College London.
A study has found that molecular patterns could better predict breast cancer recurrence.
The CMA has closed its investigation into a suspected anti-competitive discount scheme by MSD, findings no grounds for action.
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
